Moreover, one of the most landmark drugs in MM treatment is the proteasome inhibitor, bortezomib, due to its various anti-myeloma effects, such as the induction of apoptosis, alteration of the bone marrow microenvironment, and inhibition of nuclear factor kappa B (NFκB). This evidence concerns the gene NFKB1 and Miyoshi myopathy.